0.9002
Pasithea Therapeutics Corp stock is traded at $0.9002, with a volume of 35,250.
It is down -3.22% in the last 24 hours and down -47.01% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
See More
Previous Close:
$0.91
Open:
$0.9288
24h Volume:
35,250
Relative Volume:
0.01
Market Cap:
$6.56M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-0.0647
EPS:
-13.91
Net Cash Flow:
$-13.75M
1W Performance:
-3.82%
1M Performance:
-47.01%
6M Performance:
-69.12%
1Y Performance:
-85.78%
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
KTTA
Pasithea Therapeutics Corp
|
0.8811 | 6.93M | 0 | -16.28M | -13.75M | -13.91 |
![]()
ONC
Beigene Ltd Adr
|
243.72 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.38 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
594.18 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
73.56 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Pasithea’s PAS-004 shows promise in inflammatory disease study - Investing.com Australia
Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases - marketscreener.com
Pasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory Diseases - Nasdaq
Pasithea Therapeutics Announces Preclinical Data that Shows - GlobeNewswire
Breakthrough: Novel IBD Drug Outperforms FDA-Approved Treatment in Targeting Key Inflammation Pathway - Stock Titan
Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy - Yahoo Finance
Pasithea Therapeutics CEO sells shares worth $792 - Investing.com
Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site - marketscreener.com
Pasithea Therapeutics Announces Initiation of Phase 1/1B - GlobeNewswire
Phase 1/1b Trial: Pasithea's Once-Daily NF1 Drug Could Outperform Current Treatments - Stock Titan
Pasithea Therapeutics Raises $6.3 Million in Stock Offering - TipRanks
Pasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer Indications - Nasdaq
Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewswire
Pasithea Therapeutics 3.57M share Secondary priced at $1.40 - Yahoo Finance
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - Asianet Newsable
Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated By Stocktwits - Investing.com India
Pasithea Therapeutics Prices $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics announces interim data from Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - The Manila Times
Pasithea Therapeutics (KTTA) Skyrockets: Stock Soars Over 115% in Morning Trade - apnakal
$5M Public Offering: Pasithea Therapeutics Advances MEK Inhibitor Drug for Rare Disease Treatment - Stock Titan
Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results - Benzinga
Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews
Pasithea reports promising data on cancer drug PAS-004 - Investing.com
Pasithea reports promising data on cancer drug PAS-004 By Investing.com - Investing.com South Africa
Pasithea Therapeutics Reports Promising Phase 1 Trial Results for PAS-004, Demonstrating Up to 91% pERK Inhibition and Tumor Volume Reduction in Advanced Cancer Patients - Nasdaq
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 - GlobeNewswire
Phase 1 Trial Reveals 91% Target Success: New Cancer Drug Shows Promise in Pancreatic Cancer Patient - Stock Titan
Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing - marketscreener.com
AMD Stock Signals Strong Buy Ahead of Earnings - The Globe and Mail
Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients - The Manila Times
Pasithea's Cancer Drug Trial Hits Key Milestone: Latest Results from Advanced Treatment Study - Stock Titan
Pasithea Therapeutics Announces Acceptance of Abstract for ASCO 2025 Presentation on PAS-004 Clinical Trial Data - Nasdaq
Pasithea Therapeutics to Present Updated Data from Ongoing - GlobeNewswire
New PAS-004 Cancer Trial Data Shows Clinical Activity and Safety Profile | KTTA Stock News - Stock Titan
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 16.9% – Here’s What Happened - Defense World
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing C - Asianet Newsable
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Pasithea Therapeutics progresses with cancer drug trial By Investing.com - Investing.com South Africa
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial - marketscreener.com
Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga
KTTA’s Unexpected Surge: Analysis of Recent Performance - timothysykes.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Pasithea Therapeutics progresses with cancer drug trial - Investing.com
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer - MarketScreener
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pasithea Therapeutics Corp Stock (KTTA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Marques Tiago | Chief Executive Officer |
May 12 '25 |
Sale |
0.82 |
960 |
792 |
40,001 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):